Biopharmaceutical Drug Design and Development

Biopharmaceutical Drug Design and Development, Second Edition, updates the widely successful first edition, published in 1999. This new, expanded edition investigates the dozens of new biopharmaceutical drugs that have become available since the publication of the first edition. Among the drugs discussed are ones in the categories of monoclonal antibodies for in-vivo use, cytokines, growth factors, enzymes, immunomodulators, thrombolytics, and immonotherapies including vaccines. Additionally, the volume examines new and emerging technologies, such as bioinformatics, DNA microarrays, transgenics, therapeutic gene delivery, stem cells, nucleic acid-based therapeutics, and macromolecular drug delivery. Authors also study pharmacogenetics in the clinic and changes in biologic drug approval at the FDA. Biopharmaceutical Drug Design and Development, Second Edition, is a worthy sequel in the discussion on the dynamic, exciting field of biotechnology.

From the reviews of the second edition: "The book comprises 16 chapters written by 24 authors from academic and industrial laboratories in the U.S. The book is suitable for a wide audience of industrial and academic pharmaceutical scientists interested in a broad introduction to biopharmaceutical technology within the context of drug design and development. ... Overall, the book is well written with an excellent nine-page index. The chapters are generally well illustrated. ... it would be a valuable addition to industrial and academic libraries." (Aliasger K. Salem, Journal of Medicinal Chemistry, Vol. 51 (19), 2008) "This book is an update of the first edition of Biopharmaceutical Drug Development ... . this book is dedicated to quite detailed discussion of the impact the various 'omic' technologies have had on drug discovery and design. ... Overall, this is quite a useful reference book for toxicologists working in the biopharmaceutical sector, particularly if they are still getting to grips with the various 'omics' technologies and areas such stem cell therapy and gene silencing." (Peter Ryle, British Toxicological Society Newsletter, June-August, 2009)

This book provides a comprehensive examination of the newest biopharmaceutical drugs. Among the drugs discussed are ones in the categories of monoclonal antibodies for in-vivo use, cytokines, growth factors, enzymes, immunomodulators, thrombolytics, and immonotherapies including vaccines. Additionally, the volume examines new and emerging technologies, and contains a review of the Human Genome Project.

Biopharmaceutical Drug Design and Development Second Edition 1. Biotechnology: 2005 and Beyond 2. Human Genome Project 3. Bioinformatics 4. DNA Microarrays in Drug Discovery and Development 5. Microarray Technology Using Proteins, Cells, and Tissues 6. Pharmacogenetic Issues in Biopharmaceutical Drug Development 7. Transgenics 8. Therapeutic Gene Delivery 9. Stem Cells 10. Nucleic Acid Based Therapeutics 11. Therapeutic Strategies Targeting the Innate Immune Response 12. Pharmacogenetics in the Clinic 13. Molecular Modeling: Considerations for the Design of Pharmaceuticals and Biopharmaceuticals 14. Macromolecular Drug Delivery 15. Changes in Biologic Drug Approval at FDA 16. Follow On Protein Products: The Age of Biogenerics?